Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Masimo CorporationNASDAQ: MASI

Research & Development · Q1 FY2026 · quarter ended Apr 2026

Research & development declines year over year

Q1 FY2026 research & development of $30M fell 11.5% year over year, ahead of the -38.4% change in trailing-twelve-month research & development. Sequentially, it fell 6.5% from the prior quarter. Over 3 fiscal years it compounded at -12.9% a year.

Context

  • Research & development amounted to 8.3% of revenue in FY2025, down 2.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -11.5% holds above the trailing-twelve-month pace of -38.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$30M-6.5% QoQ
Last fiscal yearJan 2026
$126.4M-43.3% YoY
LTMApr 2026
$122.5M-38.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.5%——
1 year-43.3%——
3-year CAGR-12.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
126.4M USD
Year-over-year change
-43.3%
4-year CAGR
-2.0%

Research & Development vs competitors

How MASI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.4% is the lowest of 7, against a peer median of +6.6%.
  • Research & development amounts to 7.9% of revenue for MASI, versus a peer median of 4.5%.
MASI Competitors
Research & Development for MASI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BAXBaxter International Inc.LTM Jun 2026$512M USD-16.6%+4.8%4.5%
ATRAptarGroup, Inc.LTM Jun 2026$325.34M USD——8.3%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M USD-14.3%+0.0%10.1%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$179.67M USD+7.9%+15.5%64.0%
ABVXAbivax S.A.FY2025€177.76M EUR+21.3%+54.4%—
MASIMasimo CorporationLTM Apr 2026$122.5M USD-38.4%-12.9%7.9%
RGENRepligen CorporationLTM Jun 2026$55.23M USD+14.4%+7.2%7.0%
STVNStevanato Group S.p.A.LTM Jun 2026€25.44M EUR+5.3%-10.8%2.1%
MOHMolina Healthcare, Inc.LTM Sep 2026$0 USD——0.0%
HSICHenry Schein, Inc.LTM Jun 2026$0 USD——0.0%
AVTRAvantor, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding MASI) —+6.6%+6.0%4.5%

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Revenue1.24B2.04B2.05B2.09B1.53B
Cost of Revenue430.8M977M1.04B1.09B581.7M
Gross Profit808.4M1.06B1B1B945.2M
Gross Margin65.2%52.0%49.0%48.0%61.9%
Research & Development137.2M191.4M175.2M222.8M126.4M
Selling, General & Admin395.4M657.4M664M743.8M506M
Operating Expenses532.6M848.8M867M1.27B632.4M
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
EBITDA310.3M355.2M236.7M(158.7M)344.6M
EBITDA Margin25.0%17.4%11.6%-7.6%22.6%
Operating Income275.8M210M136.5M(266.7M)312.8M
Operating Margin22.3%10.3%6.7%-12.7%20.5%
Interest Income900K1.8M3M4.8M3.4M
Interest Expense300K25.7M50.3M43.6M33.2M
Other Income / Expenses(1.4M)(16.6M)(48.4M)(38.6M)(40.2M)
Income Before Tax274.4M193.4M88.1M(305.3M)272.6M
Pre-Tax Margin22.1%9.5%4.3%-14.6%17.9%
Income Tax Expense44.8M49.9M6.6M(400K)64.9M
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Net Margin18.5%7.0%4.0%-14.6%-9.9%
EPS (Basic)4.162.681.54(5.72)(2.83)
EPS (Diluted)3.982.601.51(5.72)(2.80)
Weighted Avg Shares55.17M53.6M52.8M53.3M53.6M
Weighted Avg Shares (Diluted)57.68M55.2M54.1M53.3M54.2M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.